Dossenheim, Germany

Matthias Schneider

This inventor holds 5 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Amgen Inc., Alantos Pharmaceutical Holdings, Inc., Alantos Pharmaceuticals Holding, Inc.. Active years: 2010-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthias Schneider. Retrieved from https://idiyas.com/inventor/matthias-schneider-qttw43ya

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 12.6

ph-index = 2

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2010-2014

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Matthias Schneider: Innovator in Pharmaceutical Chemistry

Introduction

Matthias Schneider is a notable inventor based in Dossenheim, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for medical applications. With a total of 5 patents to his name, Schneider's work focuses on innovative solutions for treating various diseases.

Latest Patents

Among his latest patents, Schneider has developed heterobicyclic metalloprotease inhibitors. This invention relates to amide-containing heterobicyclic compounds that exhibit increased potency against MMP-13 and MMP-3 inhibitors. Another significant patent involves dipeptidyl peptidase-IV inhibitors, which are crucial for treating Type-2 diabetes. This invention includes synthetic methods for preparing these compounds and pharmaceutical formulations for their application.

Career Highlights

Throughout his career, Matthias Schneider has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Amgen Inc. and Atlantos Pharmaceuticals Holding, Inc. His expertise in drug development has positioned him as a valuable asset in these organizations.

Collaborations

Schneider has collaborated with esteemed colleagues, including Arthur G. Taveras and Christoph Steeneck. These partnerships have further enhanced his research and development efforts in the pharmaceutical sector.

Conclusion

Matthias Schneider's innovative work in pharmaceutical chemistry has led to the development of important medical compounds. His contributions continue to impact the field positively, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…